← Back to headlines
Gilead Forecasts $1B Yeztugo Sales by 2026, Raises Business Outlook
Gilead Sciences is targeting $1 billion in sales for its drug Yeztugo by 2026 and has raised its overall base business outlook to between $29.4 billion and $29.8 billion.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
